Astragaloside IV regulates STAT1/IκB/NF-κB signaling pathway to inhibit activation of BV-2 cells.
- Author:
Yi-xin HE
;
Hai-lian SHI
;
Hong-shuai LIU
;
Hui WU
;
Bei-bei ZHANG
;
Xiao-jun WU
;
Zheng-tao WANG
- Publication Type:Journal Article
- MeSH: Animals; Astragalus Plant; chemistry; Drugs, Chinese Herbal; pharmacology; I-kappa B Proteins; genetics; metabolism; Interferon-gamma; genetics; metabolism; Mice; NF-kappa B; genetics; metabolism; Nitric Oxide; metabolism; Nitric Oxide Synthase Type II; genetics; metabolism; STAT1 Transcription Factor; genetics; metabolism; Saponins; pharmacology; Signal Transduction; drug effects; Triterpenes; pharmacology
- From: China Journal of Chinese Materia Medica 2015;40(1):124-128
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVEThe study was aimed to investigate the inhibitory effect and mechanism of astragaloside IV (ASI) on the activation of microglial cells.
METHODAfter pre-incubated with ASI for 2 h, microglial cells BV-2 were stimulated with interferon-γ (IFN-γ) for 1. 5 h and 24 h, respectively. Secretion of nitric oxide (NO) in the medium was measured by Griess method. Production of tumor necrosis factor alpha (TNF-α) was detected by ELISA approach. Cellular gene expressions of CD11b, TNF-α, interleukin 1β (IL-1β) and induced nitric oxide synthase (iNOS) were examined by quantitative-PCR analysis. Total and phosphorylation of STAT1, IκB and NF-κB was analyzed by Western blot method.
RESULTASI could significantly inhibit the increased secretion of TNF-α and NO from BV-2 cells upon IFN-γ stimulation (P < 0.001). Further study showed that ASI significantly down-regulated gene expression of IL-1β and TNF-α (P < 0.01, P < 0.05) and exhibited a trend to reduce that of iNOS. IFN-γ and ASI have no obvious effect on gene expression of CD11b. Moreover, ASI inhibited the phosphorylation of STAT1, IκB and NF-κB elicited by IFN-γ stimulation.
CONCLUSIONASI could restrain microglial activation through interfering STAT1/IκB/NF-κB signaling pathway, reducing gene expres- sion of IL-1β and TNF-α, and thus inhibiting the production of proinflammatory mediators such as NO and TNF-α.